سعر ريبكوفليكس 600مجم سي ار اقراص 2022

Pentoxifylline 600 mg controlled-release tablet marketed in Egypt by Alfacure Pharmaceuticals.

• Most frequent with the extended-release tablets: dyspepsia, nausea, vomiting, belching/flatus/bloating; digestive and CNS effects are dose related.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Recent cerebral and/or retinal haemorrhage; intolerance to pentoxifylline or other methylxanthines (caffeine, theophylline, theobromine).General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Discontinue at the first sign of an anaphylactic/anaphylactoid reaction; occasional angina, hypotension and arrhythmia reported; check for bleeding in patients at risk (recent surgery, peptic ulcer, cerebral/retinal bleeding).General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Exposure to pentoxifylline and/or active metabolites is increased in hepatic or renal impairment.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Vitamin K antagonists (e.g. warfarin)Increased prothrombin time/bleeding reported; monitor anticoagulant activity when starting or changing the dose.DailyMed (U.S. National Library of Medicine)
• TheophyllineIncreased theophylline levels and possible toxicity; monitor theophylline levels.DailyMed (U.S. National Library of Medicine)
• Strong CYP1A2 inhibitors (e.g. ciprofloxacin, fluvoxamine)May increase pentoxifylline exposure.DailyMed (U.S. National Library of Medicine)
• Antihypertensive drugsSmall decreases in blood pressure; antihypertensive dose may need reduction.DailyMed (U.S. National Library of Medicine)

• No adequate studies in pregnant women; use only if the potential benefit justifies the potential risk to the fetus.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Pentoxifylline and its metabolites are excreted in human milk; decide whether to discontinue nursing or the drug.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• More frequent prothrombin time/INR monitoring with warfarin or other vitamin K antagonists; periodic blood pressure monitoring with antihypertensives; haematocrit/haemoglobin in patients at risk of bleeding.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Pentoxifylline: Lowers blood viscosity and improves erythrocyte flexibility, increasing blood flow to the affected microcirculation (US Trental label).